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Japanese herbal (Kampo) medicine, Hochuekkito (Bu-Zhong-Yi-Qi-Tang in Chinese, TJ-41) and
Juzentaihoto (Shi-Quan-Da-Bu-Tang in Chinese, TJ-48) are well-known Kampo formulas used as tonic.
Although these medicines have separately been applied to the patients clinically depending on their
symptoms, the differences of the pharmacological activities for these medicines have not been fully
understood. TJ-48 and TJ-41 were compared for their effects on antibody response in upper respiratory
mucosal immune system in vivo. Oral administration of TJ-41 (100 mg kg
 1 per day) to early aged
BALB/c mice, which were nasally sensitized with influenza hemagglutinin vaccine, significantly
enhanced influenza virus-specific IgA and IgG antibody titers in nasal cavity and sera, respectively.
However, oral administration of TJ-48 (100 mg kg
 1 per day) failed to show the enhancing activity.
TJ-41 increased not only influenza virus-specific IgA antibody titer but also total IgA antibody titer in
nasal cavity. The stimulating activity of TJ-41 disappeared after treatment with methotrexate. The pre-
sent study strongly suggests that TJ-41 can stimulate the mucosal immune system of upper respiratory
tract, and results in enhancement of antigen-specific antibody response in upper respiratory mucosal
and systemic immune systems.
Keywords: Hochuekkito – influenza virus – Japanese herbal (Kampo) medicine – mucosal immune
system of upper respiratory tract – specific antibody response
Introduction
Formulas of traditional Japanese herbal (Kampo) medicines,
Juzentaihoto (Shi-Quan-Da-Bu-Tang in Chinese, TJ-48) and
Hochuekkito (Bu-Zong-Yi-Qi-Tang in Chinese, TJ-41) each
comprise totally 10 kinds; 5 each same and 5 each different
component herbs, and are used well clinically as tonic. TJ-48
has been applied clinically for recuperation after surgery or
chronic diseases with symptoms such as exhaustion, fatigue,
loss of appetite, pale face, dry skin and anemia whereas
TJ-41 has been used for the treatment of weak patients, who
have chronic diseases, tuberculosis, surgery with loss of
appetite, mild fever, night sweat, palpitation, fear, restlessness,
weak feeble voice, slurred speech and disturbance of vision
(1). TJ-48 is also used for the treatments of anemia, dry skin
and erosion of skin or mucosa whereas TJ-41 is used for the
patients having respiratory disorder (2).
Pharmacological activities of these medicines have been
evaluated by several research groups from the various aspects
as follows: anticancer effects (3–7), inhibition of metastasis
(8), suppression of recurrence of cancer (9), suppression of
toxicity of anticancer drugs (10,11), hematoprotective activity
(12,13), radioprotective activity (14–16), anti-infectious acti-
vity (17–21), antiallergic activity (22,23). However, few
researches on evaluation of differences in mechanisms of
action of these medicines have been tried in order to explain
the differences of the clinical efficacy of these formulas from
basic research. Although it has been reported that both medi-
cines inhibit liver metastasis of colon 26-L5 cells, TJ-41 shows
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expresses activity through activation of macrophages (8).
TJ-48 also has been shown to exhibit anti-infectious activity
against Candida albicans in cyclophosphamide-treated mice
(20). Although TJ-41 could not have the activity for this
Candida-infected mouse model, it could inhibit
predonisolone-induced Candida-infection (20,21). It is
thought that more studies are necessary to elucidate the differ-
ences of action mechanisms of these medicines in order to
understand the differences of clinical efficacy between these
Kampo medicines.
The mucosal immune system consists of an integrated net-
work of tissue, lymphoid and mucus membrane-associated
cells for regulations of host-protection, allergic diseases and
oral tolerance. Mucosal immune systems in each local site
such as gastrointestinal, pulmonary and genitourinary tracts
and the exocrine glands connect each other through lympho-
cyte homing, and this intertissue communication is named
as common mucosal immune system (CMIS) (24,25). The
Peyer’s patches in the small intestine play important roles for
CMIS as one of the inductive sites. The lymphocytes in
Peyer’s patches are rapidly eliminated from the patches, and
migrate into systemic circulation through the mesentric lymph
nodes following to the thoracic duct. The lymphocytes finally
home to the effecter sites of local mucosa such as lamina pro-
pria of intestinal and upper respiratory tracts (25). It has been
suggested that the inductive sites of CMIS also communicate
closely with systemic immune system through lymphocyte
homing (24,25), and that the mucosal immune system
regulates both local mucosal and systemic immune systems.
In classical theory of traditional herbal remedies on Chinese,
Japanese, Korean and Ayurvedic medicines, the concept of
‘spleen’ has been expressed as a functional unit for spleen
and intestine (1), which plays many roles such as nutritional
absorption, and blood and energy supplies. Therefore, it has
been considered that the dysfunction of ‘spleen’ affects the
functions of whole body (1). Classical literatures in Chinese
medicine describe that some of the herbal medicines may
have several regulating activities against the concept of
‘spleen’. These considerations can assume that a part of the
functions of ‘spleen’ resembles those of mucosal immune
system in intestine. Because traditional herbal medicines are
generally administered orally, there is a possibility that these
medicines express their clinical effects through the action on
mucosal immune system in intestine such as Peyer’s patches.
Matsumoto and Yamada, and Hong et al. have found that
TJ-48 modulates the functions of lymphocytes in Peyer’s
patches and mesenteric lymph nodes, and intraepithelial lym-
phocytes (IEL), which belong to mucosal immune system in
intestine (26,27), and the combination of some component
herbs in the formula of TJ-48 is essential for expression of
the modulating activity against immunocompetent cells of
Peyer’s patches (28). It has also been reported that lignin–
carbohydrate complexes and arabino-3,6-galactans-containing
pectic polysaccharides in TJ-48 are the active ingredients,
which enhance the function of the lymphocytes in Peyer’s
patches (intestinal immune system modulating activity)
(29,30). Recently, we have also found that TJ-41 stimulates
the function of immunocompetent cells in Peyer’s patches
(Kiyohara, Matsumo, Yamada, unpublished results). These
results postulate the possibility that these medicines may affect
mucosal immune systems in the local sites by the same or dif-
ferent mechanisms.
In the present study, we attempted to compare the efficacy of
TJ-41 and TJ-48 on the function of mucosal immune system in
upper respiratory tract, and found that these medicines have
the different effects for the mucosal immune system of upper
respiratory tract.
Materials and Methods
Materials
Spray-dried extract preparations of Juzentaihoto (Shi-Quan-
Da-Bu-Tang in Chinese, TJ-48) and Hochuekkito (Bu-Zhong-
Yi-Qi-Tang in Chinese, TJ-41) were kindly supplied by
Tsumura & Co. (Tokyo, Japan). TJ-48 for 1 day dose was
prepared as follows: a mixture of single herbs of Astragali
Radix (3 g, roots of Astragalus membranaceus Bunge),
Cinnamomi Cortex (3 g, barks of Cinnamomum cassia
Blume), Rehmanniae Radix (3 g, roots of Rehmania glutinosa
Libosch var. purpurea Makino), Paeonia Radix (3 g, roots of
Paeonia lactiflora Pall), Cnidii Rhizoma (3 g, rhizomes of
Cnidium officinale Makino), Atractylodis lanceae Rhizoma
(3 g, rhizomes of Atractylodes lancea DC.), Poria (3 g, fungi
of Poria cocos Wolf), Angelicae Radix (3 g, roots of Angelica
acutiloba Kitagawa), Ginseng Radix (3 g, roots of Panax
ginseng C.A. Meyer) and Glycyrrhizae Radix (1.5 g, roots of
Glycyrrhiza uralensis Fisch et DC.) was added to water and
extracted at 100 C for 1 h. The extracted solution was filtered
and spray-dried to obtain dry extract powder. For the prepara-
tion of TJ-41, a mixture of Astragali Radix (4 g, roots of
A. membranaceus Bunge), Atractylodis lanceae Rhizoma
(4 g, rhizomes of A. lancea DC.), Ginseng Radix (4 g, roots
of P. ginseng C.A. Meyer), Angelicae Radix (3 g, roots
of A. acutiloba Kitagawa), Bupleuri Radix (2 g, roots of
Bupleurum falcatum L.), Zizyphi Fructus (2 g, fruits of
Zizyphus jujuba Miller var. inermis Rehder), Aurantii Bobilis
Pericarpium (2 g, pericarps of ripe fruits of Citrus unshu
Markovich), Glycyrrhizae Radix (1.5 g, roots of G. uralensis
Fisch et DC.), Cimicifugae Rhizoma (1 g, rhizomes of
Cimicifuga simplex Wormskjord) and Zingiberis Rhizoma
(0.5 g, rhizomes of Zingiber officinale Roscoe) was also
extracted by the above same procedure to obtain dry extract
powder. Ministry of Health, Labour and Welfare in Japan
chose each 5 g of TJ-48 and TJ-41 as a dosage for 1 day for
adult human. In the present study, the dosages of the medicines
were calculated from their 1 day dosages for adult human.
Three-dimensional HPLC (3D-HPLC) analyses were carried
out to know broad chemical profiles of TJ-48 and TJ-41, and
the spray-dried extract preparations of TJ-41 and TJ-48
460 Mucosal immunity potentiation and Kampo medicinesshowing 3D-HPLC profiles as in Figs 1 and 2 were used for the
present study.
Vaccines
Influenza A/PR/8 hemagglutinin (HA) vaccine was prepared
from mouse-adapted influenza virus A/PR/8/34 according
to the methods of Nagai and Yamada (31). Mouse-adapted
influenza viruses A/PR/8/34 (H1N1), which were preserved
in The Kitasato Institute (Tokyo, Japan), were grown in allan-
toic cavity of 10 days old embryonated eggs for 48 h at 34 C.
The allantoic fluid containing live viruses was harvested and
centrifuged at 1000 g for 20 min. The virus was recovered
from the resulting supernatant by sucrose density centrifuga-
tion, and the vaccine was prepared by inactivation with ether,
according to the method of Davenport et al. (32).
A split vaccine of influenza HA vaccine produced from
influenza virus A/New Caledonia/20/99 (A/NC/20) was kindly
supplied from Center for Biologicals of The Kitasato Institute
(Saitama, Japan) (influenza A/NC/20 HA vaccine).
Mice
Specific pathogen-free female BALB/c mice of 7 weeks old
(young) and 6 months old (early aged) were purchased
from Japan SLC (Shizuoka, Japan). The animals were housed
in plastic cages in an air-conditioned room at 23 ± 2 C with
a relative humidity of 55 ± 10% under a 12 h light/dark cycle,
fed a standard laboratory diet and given water ad libitum.
Animal experiments were performed according to the animal
care guidelines of The Kitasato Institute and Kitasato
University.
Immunization
Mice were anesthetized by intraperitoneal injection of sodium
amobarbital (Sigma, 0.2 ml per mouse in a sterilized saline
solution at 11 mg ml
 1), and then immunized by a primary
intranasal inoculation of 1, 2.5 or 5 mg of HA vaccines in ster-
ilized phosphate-buffered saline (PBS) (10 ml each) at Day 0.
The mice were given a secondary intranasal inoculation of
the vaccine at the same dose as the primary immunization at
28 days (Day 28) after the primary immunization by the above
same procedure.
Administrations of Medicines
The mice were administered orally aqueous solutions of TJ-48
and TJ-41 at doses of 100 mg kg
 1 per day (0.5 ml per mouse)
from 7 days before the primary immunization (Day  7) to
14 days after the secondary immunization (Day 42) once a
day. Methotrexate (20 mg kg
 1, Takeda Pharmaceutical Co.
Ltd, 200 ml per mouse) was also administered orally to the
early aged mice twice at 3 days each before the primary and
secondary immunizations (Day  3 and Day 25).
Figure 1. 3D-HPLC profiles of Hochuekkito (TJ-41).
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The procedure was performed according to the method of
Nagai et al. (33). Briefly, at 21 days after the primary immuni-
zation (Day 21), the blood sample was taken from the retro-
orbital plexus of mice by a glass capillary, and the serum
sample was separated from the blood by centrifugation after
standingfor 2hat room temperature. At 42 days after the prim-
ary immunization, mice were sacrificed using ether and then
bled from the heart with syringe to prepare sera as described
above. After bleeding, the head of the mouse was removed,
and the lower jaw of the mouse was excised. A hypodermic
needle was inserted into the posterior opening of the nasophar-
ynx, and 2 ml of sterilized PBS containing 0.1% bovine serum
albumin (BSA) was injected to collect the nasal wash. The
nasal washes were centrifuged to remove cellular debris and
stored at  80 C prior to use for antibody analysis.
ELISA for Influenza Virus-specific and Total IgA
Antibodies
The titers of influenza virus-specific antibodies in the sera
(IgG class) and nasal washes (IgA class) were measured by
ELISA according to the procedure of Nagai et al. (33). Briefly,
the wells of a 96-well ELISA plate (ImmunomMaxisorp,
Nunc) were coated with 100 ml of the influenza HA vaccines
(5 mgm l
 1) in 10 mM carbonate/bicarbonate buffer, pH 9.6.
The plate was incubated for 2 h at room temperature, and
then washed three times with 200 ml of PBS containing
0.05% Tween 20 and 0.1% NaN3 (PBS–Tween). PBS contain-
ing 0.5% skim milk and 0.1% NaN3 (blocking buffer) was
placed in the wells (200 ml), and incubated overnight at 4 C.
After washing the plate with PBS–Tween three times, each
sample of serum or nasal wash (100 ml) was added to a set of
three wells. Because IgA and IgG antibodies in the samples
of nasal washes and sera recognize the same antigenic
epitope of the influenza HA vaccines, the IgA and IgG anti-
bodies in the samples were separated by Protein G-Sepharose
in advance. Samples for ELISA were prepared as follows: Pro-
tein G–Sepharose (about 300–400 ml, Sigma) packed into
Ultra-free-MC centrifuge column units with low binding Dura-
pore membrane (pore size 0.45 mm; Millipore) was equili-
brated with 20 mM sodium phosphate buffer, pH 7.0
(binding buffer). The nasal wash (200 ml) or serum (5 ml)
was applied to the Protein G-Sepharose column and
centrifuged at 1000 r.p.m. until all the solutions were loaded
into the gel. The column was washed with the binding buffer
(200 ml each) twice to obtain the unabsorbed fraction as IgA
antibody fraction. The bound IgG antibody in the column
was further eluted from the column with 200 ml each of
0.1 M glycine–HCl buffer, pH 2.7, twice into the plastic tubes
Figure 2. 3D-HPLC profiles of Juzentaihoto (TJ-48).
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The unabsorbed and absorbed fractions each were diluted with
the blocking buffer (25 times for the samples from the sera;
twice for those from the nasal washes) and placed on the
wells of influenza HA vaccine-immobilized ELISA plate.
The plates were incubated for 2 h at room temperature and
washed three times with PBS–Tween. Alkaline phosphatase
coupled goat anti-mouse IgA (Zymed) or IgG (Sigma) anti-
body diluted with the blocking buffer (1:1000) was added to
each well (100 ml per well). The plates were incubated over-
night at room temperature, and then washed four times with
PBS–Tween. Finally, p-nitrophenylphosphate (Wako Pure
Chemical Co. Ltd, 1 mg ml
 1) in 10% diethanolamine buffer,
pH 9.8 (150 ml), was added to each well. After incubation at
room temperature, the absorbance of the well was measured
at 405 nm by a Microplate Reader (Model 450, Bio-Rad).
Total IgA in nasal wash was also measured by ELISA
according to the procedure of Nagai et al. (33). Goat anti-
mouse IgA antibody (Pharmingen (5 mgm l
 1, 100 ml)) in 10
mM carbonate/bicarbonate buffer (pH 9.6) containing 0.01%
BSA was incubated in a 96-well ELISA plate for 3 h at
37 C, and the plate was washed four times with PBS–Tween.
After the plate was incubated with the above same blocking
buffer (250 ml) for 1 h at 37 C, the plate was washed four times
with PBS–Tween. The nasal washes were diluted with
SuperBlock blocking buffer (Pierce) containing 0.05% Tween
20 (1:40), and the wells were incubated with the diluted
nasal washes (100 ml) for 1 h at 37 C. After the plate was
washed four times with PBS–Tween, the wells were incubated
with alkaline phosphatase-coupled anti-mouse IgA antibody
(1:1000) in the blocking buffer for 1 h at 37 C, and the
plate was washed four times with PBS–Tween. The bound
alkaline phosphatase activity was measured by the same
procedure as described above.
Statistics
All results are expressed as the mean ± SEM. The significance
of differences between experimental groups was analyzed with
ANOVA followed by Fisher’s PLSD procedure. The probabi-
lity (P) values < 0.05 were considered significant.
Results
Do TJ-41 and TJ-48 Enhance Primary Antibody
Response in the Systemic Immune System?
It has been known that primary intranasal inoculation of the
antigen induces antigen-specific antibody response in systemic
immune system through upper respiratory mucosal immune
system to result in the elevation of antigen-specific antibody
titer in blood stream, and that secondary intranasal inoculation
of antigen additively induces the elevation of antigen-specific
antibody level of secretory IgA class in nasal cavity (34). In the
present study, we attempted to evaluate whether TJ-41 and
TJ-48 can stimulate antibody response in systemic immune
system through upper respiratory mucosal immune system by
using primary intranasal inoculation of influenza HA vaccine.
Young female BALB/c mice of 7 weeks old (young mice)
were intranasally inoculated primarily with the influenza A/
PR/8 HA vaccine (5 mg per mouse) at Day 0. The mice were
also orally administered with TJ-41 or TJ-48 at a dose of
100 mg kg
 1 per day from 7 days before (Day  7) to
21 days (Day 21) after the vaccine inoculation. Then the
influenza virus-specific IgG antibody titers in the sera of the
mice at Day 21 were measured. Oral administration of TJ-41
significantly enhanced the influenza virus-specific IgG anti-
body titers whereas TJ-48 had no effect (Fig. 3A). TJ-41 and
TJ-48 have been often used for the patients having debilitated
conditions. It has been reported that BALB/c mice of 6 months
old show the significantly lower antibody response espe-
cially of antigen-specific IgG class antibody against T cell-
dependent antigen than young BALB/c mice of 7 weeks old
(35). Koga et al. and Hagiwara et al. also have found that
both mucosal immune functions in intestine and upper respira-
tory tract of mice are diminished during aging (36,37). There-
fore, the effects of TJ-41 and TJ-48 on the antibody response
against primary intranasal inoculation of the influenza HA
vaccine were also studied by using BALB/c mice of 6 months
old (early aged mice). TJ-41 and TJ-48 each were orally
administered by the above same schedule to the early aged
BALB/c mice, which were given primary intranasal inocula-
tion of the influenza A/PR/8 HA vaccine. TJ-41 also enhanced
significantly the titer of anti-influenza virus-specific IgG anti-
body in the sera at Day 21 as observed in the young mice; how-
ever, TJ-48 did not affect the titer even in the early aged mice
(Fig. 3B).
TJ-41 Enhances IgA Antibody Response in
Early Aged Mice
In order to evaluate the effects of TJ-48 and TJ-41 on antigen-
specific IgA antibody titer in upper respiratory tract, the model
mice that received secondary intranasal immunization with
influenza HA vaccine was employed. Early aged and young
Figure 3. Comparison of effects of oral administrations of TJ-41 and TJ-48
(100 mg kg
 1 per day each) on influenza virus-specific IgG antibody titers
in sera of young (A) and early aged BALB/c mice (B) against primary
intranasal inoculation of influenza A/PR/8 HA vaccine (5 mg per mouse).
Influenza virus-specific IgG antibody titer was measured for the sera collected
on Day 21 by ELISA as described in Materials and Methods.
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influenza A/PR/8 HA vaccine at Day 0 and Day 28, and
TJ-41 and TJ-48 each were orally administered to the mice
from 7 days (Day  7) before to 42 days (Day 42) after the
primary inoculation of the vaccine. The nasal washes were
collected at Day 42 from the mice, and the titer of influenza
virus-specific IgA antibody was measured. TJ-41 significantly
enhanced influenza virus-specific IgA antibody titer in nasal
washes of the early aged BALB/c mice whereas TJ-48 showed
no activity (Fig. 4B). However, neither TJ-41 nor TJ-48 had
any effect on the IgA antibody titer in the nasal washes of
the young mice (Fig. 4A). The influenza virus-specific IgG
antibody titer was also measured for the sera from secondary
immunized BALB/c mice at Day 42, and oral administration
of TJ-41 increased the influenza virus-specific IgG antibody
titers in the sera of both young and early aged mice (Fig. 5).
However, oral administration of TJ-48 had no effect in both
mice (Fig. 5).
In order to know whether TJ-41 enhances a basic level of
secretory IgA production in upper respiratory mucosal
immune system, total IgA titer in nasal wash of early aged
mice, who were administered TJ-41 and intranasally immu-
nized with different amounts of influenza HA vaccine, was
analyzed. TJ-41 (100 mg kg
 1 per day) was administered
orally to the early aged BALB/c mice, which were secondary
immunized with different doses (1.0, 2.5 and 5.0 mg per
mouse) of intranasal inoculations of influenza A/NC/20 HA
vaccine, and the total and influenza virus-specific IgA anti-
body titers were measured for the nasal washes. TJ-41 signifi-
cantly enhanced total IgA titer as well as the influenza
virus-specific IgA antibody titer in the nasal washes of the
mice, which were immunized with 5.0 mg per mouse of the
influenza vaccine (Fig. 6), suggesting that TJ-41 enhances
basic level of secretory IgA production in upper respiratory
mucosal immune system of the early aged mice.
Methotrexate Treatment Suppressed the Stimulating
Activity of TJ-41
Methotrexate is a well-known anticancer drug, and usually
used for inductions of acute injury in small intestine and
impairment of intestinal immune system in animal studies
(38,39). Administration of methotrexate (20 mg kg
 1) has
been reported to reduce total IgA titer in the intestinal fluids
of rats (39). We also reconfirmed that the administration of
methotrexate to BALB/c mice also diminished total IgA titers
in mouse feces (data not shown). By this condition, methotrex-
ate did not seem to decrease notably antigen-specific antibody
responses in systemic immune system and upper respiratory
mucosal immune system against intranasally inoculated
influenza HA vaccine (Fig. 7). Effect of methotrexate on the
stimulating activity of TJ-41 for influenza viral antigen-
specific antibody responses in both immune systems was
examined. The early aged BALB/c mice, which were
secondary immunized with intranasal inoculation of influenza
A/PR/8 HA vaccine, were administered orally with metho-
trexate (20 mg kg
 1) twice at 3 days before the primary and
Figure 4. Comparison of effects of oral administrations of TJ-41 and TJ-48
(100 mg kg
 1 per day each) on influenza virus-specific IgA antibody titers
in nasal washes of young (A) and early aged BALB/c mice (B) against
secondary intranasal inoculation of influenza A/PR/8 HA vaccine (5 mg per
mouse). Influenza virus-specific IgA antibody titers were measured for the
nasal washes collected at Day 42 by ELISA.
Figure 5. Comparison of effects of oral administrations of TJ-41 and TJ-48
(100 mg kg
 1 per day each) on influenza virus-specific IgG antibody titers
in sera of young (A) and early aged BALB/c mice (B) against secondary
intranasal inoculation of influenza A/PR/8 HA vaccine (5 mg per mouse).
Influenza virus-specific IgG antibody titer was measured for the sera collected
at Day 42 by ELISA.
Figure 6. Effect of oral administration of TJ-41 (100 mg kg
 1 per day) on
influenza virus-specific IgA antibody titer (A) and total IgA antibody titer
(B) in nasal washes of early aged BALB/c mice which were immunized with
secondary intranasal inoculation of different doses (1.0, 2.5 and 5.0 mg per
mouse) of influenza A/NC/20 HA vaccine.
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were administered with TJ-41 or TJ-48 at a dose of 100 mg
kg
 1 per day from Day  7 to Day 42. TJ-41 failed to increase
the influenza virus-specific antibody titers in both sera and
nasal washes at Day 42 (Fig. 7).
Discussion
The present study clearly indicates that Hochuekkito (Bu-
Zong-Yi-Qi-Tang, TJ-41) potentiates the function of mucosal
immune system in upper respiratory tract especially for the
early aged mice, whereas Juzentaihoto (Shi-Quan-Da-
Bu-Tang, TJ-48) failed to stimulate the same immune system
although TJ-48 modulates the function of immunocompetent
cells in Peyer’s patches as one of the inductive sites for
mucosal immune system (26,27). TJ-41 has been often used
for patients having respiratory symptoms, especially those
patients who cannot recover well from cold syndrome;
however, TJ-48 has not been applied for treatment of cold
syndrome clinically (2). Mori et al. (40) have reported that
TJ-41 increases IFN-a level in bronchoalveolar lavage fluid
(BALF) of influenza virus-infected mice in early stages of
the infection. Therefore, the stimulating actions of TJ-41 on
both IFN-a production and antibody responses in upper respi-
ratory mucosal immune system are able to explain well its
clinical effect on patients having cold syndrome. Although
TJ-41 and TJ-48 have separately been applied clinically for
recovery from fatigue of whole body depending on the symp-
toms of patients, differences of the action mechanism of
these medicines have little been understood. The present study
postulates a possibility that differences in the action
mechanisms between TJ-41 and TJ-48 can be resolved from
clarification of their actions on upper respiratory mucosal
immune system.
The present study clearly indicated that TJ-41 potentiated
total and the antigen-specific IgA production in upper respira-
tory mucosal immune system of only early aged mice but not
in young mice. Hagiwara et al. (37) have reported that aged
mice have diminished antigen-specific IgA responses in upper
respiratory mucosal immune system compared to young mice
in the presence of little dosage of an adjuvant, cholera toxin.
Therefore, it is postulated that TJ-41 may be able to potentiate
only the downregulated upper respiratory mucosal immune
system.
It has been proposed that upper respiratory mucosal immune
systems are regulated partially by lymphocyte homing from
intestinal Peyer’s patches through CMIS (25,34). The stimulat-
ing activity of TJ-41 on upper respiratory mucosal immune
system disappeared by impairment of intestinal immune sys-
tem with methotrexate treatment. However, methotrexate
alone seemed not to reduce the upper respiratory mucosal
immune function of BALB/c mice at the dose used in the pre-
sent study (Fig. 7). Because TJ-41 stimulates immunocompe-
tent cells of Peyer’s patches in vitro (Kiyohara, Matsumo,
Yamada, unpublished results), there is a possibility that
TJ-41 may express stimulating activity on upper respiratory
mucosal immune system through modulation of functions of
immunocompetent cells in intestinal Peyer’s patches. As
another action mechanisms of TJ-41, the possibility also still
remains that the active ingredients of TJ-41 may stimulate
the upper respiratory mucosal immune function directly after
its absorption from digestive system.
The present study indicated that TJ-41 strongly enhanced
antigen-specific IgG response in systemic immune system
against the intranasally administered antigen in both young
and early aged mice, but TJ-48 did not. TJ-48 as well as
TJ-41 has been reported to enhance antigen-specific IgG
response when the antigens were administered intraperi-
toneally (41). It has been proposed that upper respiratory
mucosal immune system contributes to the induction of
antibody responses on not only upper respiratory tract but
also spleen and peripheral lymph nodes as systemic immune
system (34). Therefore, TJ-41 may enhance the antigen-
specific IgG response in systemic immune system against
intranasally inoculated antigen by potentiating the function
of upper respiratory mucosal immune system toward systemic
immune system. Since the stimulating activity of TJ-41 on
systemic immune system against intranasally inoculated
antigen was observed even in young mice, the action mecha-
nism of TJ-41 for expression of this stimulating activity is con-
sidered to be different from those for the stimulating activity
on secretory IgA antibody response in upper respiratory tract.
However, the mechanism of regulation of immunocompetent
cells in systemic immune system through upper respiratory
mucosal immune system has not been well known (34). There-
fore, the comprehensive analysis on the effects of TJ-41
against intestinal immune system as well as upper respiratory
Figure 7. Effect of pretreatment with methotrexate on enhanced activity of
oral administration of TJ-41 against influenza virus-specific IgG antibody
response in sera (A) and of influenza virus-specific IgA antibody response in
nasal washes (B) of early aged BALB/c mice. Early aged BALB/c mice, which
were secondary immunized with intranasal inoculation of influenza A/PR/8
HA vaccine, were administered orally with methotrexate (20 mg kg
 1) twice
at Day  3 and Day 25, and the mice were also administered with TJ-41 or
TJ-48 (100 mg kg
 1 per day) from Day  7 to Day 42. Influenza virus-specific
IgG and IgA antibodies were measured for sera and nasal washes collected at
Day 42, respectively.
eCAM 2006;3(4) 465mucosal immune system is required for understanding action
mechanism of TJ-41 on mucosal immune system.
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